Abstract |
The activity of phosphohexose isomerase [PHI] was measured in 48 primary carcinomas from patients with breast cancer, and its usefulness as a predictor of response to cytotoxic drugs at the metastatic stage was evaluated. There was a statistically significant difference in the activity of PHI between responders and non-responders to these treatments. These preliminary findings are currently being evaluated in an extended series.
|
Authors | I Mitchell, N Deshpande, R Millis, R D Rubens |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 17
Issue 3
Pg. 289-91
( 1986)
ISSN: 0344-5704 [Print] Germany |
PMID | 3742715
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Glucose-6-Phosphate Isomerase
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Breast Neoplasms
(drug therapy, enzymology)
- Glucose-6-Phosphate Isomerase
(metabolism)
- Humans
- Neoplasm Metastasis
- Prognosis
|